Louis Philipson to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications Louis Philipson has written about Diabetes Mellitus, Type 2.
Connection Strength
4.973
-
Objective and Subjective Sleep Patterns in Adults With Maturity-Onset Diabetes of the Young (MODY). Diabetes Care. 2023 03 01; 46(3):608-612.
Score: 0.453
-
Precision diabetes: Lessons learned from maturity-onset diabetes of the young (MODY). J Diabetes Investig. 2022 Sep; 13(9):1465-1471.
Score: 0.432
-
Approach to the Patient with MODY-Monogenic Diabetes. J Clin Endocrinol Metab. 2021 01 01; 106(1):237-250.
Score: 0.390
-
Harnessing heterogeneity in type 2 diabetes mellitus. Nat Rev Endocrinol. 2020 02; 16(2):79-80.
Score: 0.366
-
GCK-MODY in the US National Monogenic Diabetes Registry: frequently misdiagnosed and unnecessarily treated. Acta Diabetol. 2016 Oct; 53(5):703-8.
Score: 0.282
-
Resting beta-cells - A functional reserve? Diabetes Metab. 2016 Jun; 42(3):157-61.
Score: 0.277
-
Genome wide association studies for diabetes: perspective on results and challenges. Pediatr Diabetes. 2013 Mar; 14(2):90-6.
Score: 0.225
-
Who should have genetic testing for maturity-onset diabetes of the young? Clin Endocrinol (Oxf). 2011 Oct; 75(4):422-6.
Score: 0.205
-
Glucose-induced ERM protein activation and translocation regulates insulin secretion. Am J Physiol Endocrinol Metab. 2010 Nov; 299(5):E772-85.
Score: 0.190
-
Cold climate genes and the prevalence of type 2 diabetes mellitus. Med Hypotheses. 2006; 67(5):1034-41.
Score: 0.143
-
Reactive species, cellular repair and risk factors in the onset of type 2 diabetes mellitus: review and hypothesis. Curr Diabetes Rev. 2006 May; 2(2):241-59.
Score: 0.141
-
Reactive species and early manifestation of insulin resistance in type 2 diabetes. Diabetes Obes Metab. 2006 Mar; 8(2):136-45.
Score: 0.139
-
Oxidative reactive species in cell injury: Mechanisms in diabetes mellitus and therapeutic approaches. Ann N Y Acad Sci. 2005 Dec; 1066:136-51.
Score: 0.137
-
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Ann Intern Med. 2023 04; 176(4):eL230007.
Score: 0.114
-
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study. Ann Intern Med. 2022 10; 175(10):1392-1400.
Score: 0.110
-
ADA/EASD Precision Medicine in Diabetes Initiative: An International Perspective and Future Vision for Precision Medicine in Diabetes. Diabetes Care. 2022 02 01; 45(2):261-266.
Score: 0.105
-
Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis. J Gen Intern Med. 2022 02; 37(2):439-448.
Score: 0.104
-
The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis. J Gen Intern Med. 2022 02; 37(2):415-438.
Score: 0.102
-
Exenatide extended release in patients with type 1 diabetes with and without residual insulin production. Diabetes Obes Metab. 2020 11; 22(11):2045-2054.
Score: 0.095
-
Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2). Diabetes. 2019 08; 68(8):1565-1576.
Score: 0.087
-
GCK-MODY in the US Monogenic Diabetes Registry: Description of 27 unpublished variants. Diabetes Res Clin Pract. 2019 May; 151:231-236.
Score: 0.087
-
Management and pregnancy outcomes of women with GCK-MODY enrolled in the US Monogenic Diabetes Registry. Acta Diabetol. 2019 Apr; 56(4):405-411.
Score: 0.085
-
TCF1 links GIPR signaling to the control of beta cell function and survival. Nat Med. 2016 Jan; 22(1):84-90.
Score: 0.069
-
Routine depression screening for patients with diabetes--reply. JAMA. 2014 Dec 10; 312(22):2413.
Score: 0.064
-
The mental health comorbidities of diabetes. JAMA. 2014 Aug 20; 312(7):691-2.
Score: 0.063
-
Insulin regulates carboxypeptidase E by modulating translation initiation scaffolding protein eIF4G1 in pancreatic ß cells. Proc Natl Acad Sci U S A. 2014 Jun 03; 111(22):E2319-28.
Score: 0.062
-
Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in ß cells. Cell Metab. 2014 Jan 07; 19(1):109-21.
Score: 0.060
-
Lean versus obese diabetes mellitus patients in the United States minority population. J Diabetes Complications. 2014 Jul-Aug; 28(4):500-5.
Score: 0.060
-
Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications. Diabetes Care. 2014; 37(1):202-9.
Score: 0.059
-
A brief perspective on insulin production. Diabetes Obes Metab. 2009 Nov; 11 Suppl 4:189-96.
Score: 0.045
-
Leptin deficiency and beta-cell dysfunction underlie type 2 diabetes in compound Akt knockout mice. Mol Cell Biol. 2009 Jun; 29(11):3151-62.
Score: 0.043
-
When BAD is good for beta cells. Cell Metab. 2008 Apr; 7(4):280-1.
Score: 0.040
-
Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes. Diabetes. 2008 Apr; 57(4):1131-5.
Score: 0.040
-
Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020 09; 63(9):1671-1693.
Score: 0.024
-
Integrated Pancreatic Blood Flow: Bidirectional Microcirculation Between Endocrine and Exocrine Pancreas. Diabetes. 2020 07; 69(7):1439-1450.
Score: 0.023
-
Deletion of Protein Kinase D1 in Pancreatic ß-Cells Impairs Insulin Secretion in High-Fat Diet-Fed Mice. Diabetes. 2018 01; 67(1):71-77.
Score: 0.020
-
NIDDM is associated with loss of pancreatic beta-cell L-type Ca2+ channel activity. Am J Physiol. 1996 Jan; 270(1 Pt 1):E133-40.
Score: 0.017
-
Defective glucose-dependent endoplasmic reticulum Ca2+ sequestration in diabetic mouse islets of Langerhans. J Biol Chem. 1994 Jul 15; 269(28):18279-82.
Score: 0.016